[Study of the platelet GP specific antibodies and HLA antibodies expression in platelet transfusion refractoriness patients]
- PMID: 21122318
[Study of the platelet GP specific antibodies and HLA antibodies expression in platelet transfusion refractoriness patients]
Abstract
Objective: To investigate the correlation between the platelet GP specific antibodies/HLA antibodies and platelet transfusion refractoriness (PTR).
Methods: Sixty-five patients with PTR were selected in this study and were genotyped for HLA-A and HLA-B as well as HPA systems by standard PCR-SSP assays. The platelet GP specific antibodies and HLA antibodies in serum and platelet elution were tested with a solid phase ELISA.
Results: The HLA-A/B antigens and the frequencies of HPA-1, 2, 4, 5, 6, 9, 15 antigens in PTR patients had no difference from those in healthy donors. The freguencies of HPA-3a and 3b were 0.65 and 0.35, respectively. There was statistical difference between the 65 PTR patients and the healthy donors in HPA-3 freguencies (P < 0.05). Twenty-four patients (36.9 %) only expressed HLA antibodies, and 14 (21.5%) expressed HLA and platelet GP specific antibodies. The highest expression of anti-HLA-A/B specific antibodies was -A*9(46.2 %)/-B*40(33.6%), respectively. In serum, GPIIb/IIIa was expressed (26.2%), followed by GPIa/IIa (21.5 %). In platelet elution, GPIIb/IIIa was expressed of 41.5% and GPIb/IX 41.5%. Pedigree study was carried out for 2 patients. The results showed that the platelet GP specific antibody/HLA antibody developed in PTR patients was highly related to the mismatch with the platelet antigen/HLA antigen in their parents.
Conclusion: The expressions of the HLA and platelet GP specific antibodies are the most important reason in PTR, it's meaningful to explore the correlation between PTR and HLA and HLA-A/B antigen in guiding platelet transfusion.
Similar articles
-
Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.Transfus Med. 2018 Feb;28(1):40-46. doi: 10.1111/tme.12423. Epub 2017 May 18. Transfus Med. 2018. PMID: 28516675
-
HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.Transfus Apher Sci. 2015 Jun;52(3):295-9. doi: 10.1016/j.transci.2014.12.028. Epub 2014 Dec 30. Transfus Apher Sci. 2015. PMID: 25620758
-
Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China.Transfus Med. 2010 Aug 1;20(4):269-74. doi: 10.1111/j.1365-3148.2010.00995.x. Epub 2010 Feb 4. Transfus Med. 2010. PMID: 20136782
-
[Platelet transfusion refractoriness and effective management of platelet alloimmunization].Nihon Rinsho. 1997 Sep;55(9):2392-8. Nihon Rinsho. 1997. PMID: 9301306 Review. Japanese.
-
[Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].Transfus Clin Biol. 2014 Nov;21(4-5):193-206. doi: 10.1016/j.tracli.2014.08.140. Epub 2014 Sep 30. Transfus Clin Biol. 2014. PMID: 25277423 Review. French.
Cited by
-
Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis.Front Med (Lausanne). 2022 May 6;9:873500. doi: 10.3389/fmed.2022.873500. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35602482 Free PMC article.
-
Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients.Oncol Lett. 2017 Aug;14(2):1445-1448. doi: 10.3892/ol.2017.6270. Epub 2017 May 26. Oncol Lett. 2017. PMID: 28789362 Free PMC article.
-
[Study on the expression of T, B lymphocyte antigen and platelet antibodies in patients with platelet transfusion refractoriness].Zhonghua Xue Ye Xue Za Zhi. 2016 Mar;37(3):238-41. doi: 10.3760/cma.j.issn.0253-2727.2016.03.013. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 27033764 Free PMC article. Chinese.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
